Abstract

Indirect estimation methods are required for estimating the size of populations where only a proportion of individuals are observed directly, such as problem drug users (PDUs). Capture-recapture and multiplier methods are widely used, but have been criticized as subject to bias. We propose a new approach to estimating prevalence of PDU from numbers of fatal drug-related poisonings (fDRPs) using linked databases, addressing the key limitations of simplistic 'mortality multipliers'. Our approach requires linkage of data on a large cohort of known PDUs to mortality registers and summary information concerning additional fDRPs observed outside this cohort. We model fDRP rates among the cohort and assume that rates in unobserved PDUs are equal to rates in the cohort during periods out of treatment. Prevalence is estimated in a Bayesian statistical framework, in which we simultaneously fit regression models to fDRP rates and prevalence, allowing both to vary by demographic factors and the former also by treatment status. We report a case study analysis, estimating the prevalence of opioid dependence in England in 2008/09, by gender, age group and geographical region. Overall prevalence was estimated as 0.82% (95% credible interval=0.74-0.94%) of 15-64-year-olds, which is similar to a published estimate based on capture-recapture analysis. Our modelling approach estimates prevalence from drug-related mortality data, while addressing the main limitations of simplistic multipliers. This offers an alternative approach for the common situation where available data sources do not meet the strong assumptions required for valid capture-recapture estimation. In a case study analysis, prevalence estimates based on our approach were surprisingly similar to existing capture-recapture estimates but, we argue, are based on a much more objective and justifiable modelling approach.

Highlights

  • Information on the size of the injecting and opioid-using population globally is increasingly important to support and motivate public health strategies to eliminate hepatitis C virus (HCV) [1,2,3,4,5], reverse upward trends in opioid overdose deaths [6,7] and monitor treatment provision [7,8]

  • We first describe several common criticisms of multiplier methods, which we aim to address with our proposed approach

  • We focus on mortality multipliers in this text, but the same general criticisms apply to other types of multipliers, e.g. treatment multipliers

Read more

Summary

Introduction

Information on the size of the injecting and opioid-using population globally is increasingly important to support and motivate public health strategies to eliminate hepatitis C virus (HCV) [1,2,3,4,5], reverse upward trends in opioid overdose deaths [6,7] and monitor treatment provision [7,8]. There are discrepancies in global estimates of the prevalence of injecting and other problem drug use, as well as inconsistencies in and controversies concerning national and city-level estimates. It is unclear what is the original method or source data for US estimates [8,12,13,14]. National estimates of injecting drug use were found to be inconsistent with information on Addiction. Methods Our approach requires linkage of data on a large cohort of known PDUs to mortality registers and summary information concerning additional fDRPs observed outside this cohort. Prevalence is estimated in a Bayesian statistical framework, in which we simultaneously fit regression models to fDRP rates and prevalence, allowing both to vary by demographic factors and the former by treatment status

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call